AASDH: A Promising Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Target Name: AASDH

NCBI ID: G132949

AASDH

AASDH: A Promising Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Alzheimer's disease is a debilitating and progressive neurological disorder that affects millions of people worldwide. It is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to the degenerative loss of cognitive, linguistic, and social functions. While currently there is no cure for Alzheimer's disease, the development of new treatments and biomarkers has the potential to slow down or even reverse the disease's progression. In this article, we will discuss AASDH (ACSF4), a drug target and biomarker for the treatment of Alzheimer's disease.

The Aging Brain

As we age, the brain undergoes a series of changes that contribute to the development and progression of Alzheimer's disease. One of the earliest changes is the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. These tangles and plaques are composed of abnormal aggregates of the protein tau and beta-amyloid, respectively. The accumulation of these tangles and plaques leads to the formation of neuroinaries, which are the sites of neurofibrillary tangles and beta-amyloid plaques. Over time, these tangles and plaques can cause the destruction of nerve cells, leading to the degenerative loss of cognitive, linguistic, and social functions associated with Alzheimer's disease.

AASDH: A Potential Drug Target

AASDH is a protein that is expressed in the brain and has been shown to be involved in the formation of neurofibrillary tangles and beta-amyloid plaques. It is a small fragment of the protein APP (amyloid precursor protein), which is a normal protein that is present in the brain. When APP is processed by the enzyme ApoCPU (amyloid precursor protein convertase), it becomes AASDH.

AASDH has been shown to interact with several other proteins, including ApoB120, a protein that is also involved in the formation of beta-amyloid plaques. AASDH has also been shown to interact with the protein TSP3, which is involved in the formation of neurofibrillary tangles.

AASDH as a drug target

AASDH has the potential to be a drug target for the treatment of Alzheimer's disease because it is involved in the formation of both neurofibrillary tangles and beta-amyloid plaques, which are the hallmark hallmarks of Alzheimer's disease. Several studies have shown that blocking AASDH can significantly reduce the formation of neurofibrillary tangles and beta-amyloid plaques in animal models of Alzheimer's disease.

One of the reasons why AASDH is considered a potential drug target is its expression in the brain, which makes it a promising target for small molecule inhibitors. Several studies have shown that inhibitors of AASDH have the potential to reverse the cognitive and behavioral deficits associated with Alzheimer's disease.

AASDH as a biomarker

In addition to its potential as a drug target, AASDH has also been shown to be a potential biomarker for the treatment of Alzheimer's disease. The accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain is a hallmark of Alzheimer's disease, and the detection of these tangles and plaques in the brain is a key diagnostic marker for the disease.

AASDH has been shown to be involved in the formation of both neurofibrillary tangles and beta-amyloid plaques, which are the hallmark hallmarks of Alzheimer's disease. Several studies have shown that blocking AASDH can significantly reduce the formation of neurofibrillary tangles and beta-amyloid plaques in animal models of Alzheimer's disease.

Conclusion

In conclusion, AASDH is a protein that is involved in the formation of neurofibrillary tangles and beta-amyloid plaques, which are the hallmark hallmarks of Alzheimer's disease. Its potential as a drug target and biomarker make it an attractive target for the development of new treatments for Alzheimer's disease. Further research is needed to fully understand the role of AASDH in the treatment of Alzheimer's disease.

Protein Name: Aminoadipate-semialdehyde Dehydrogenase

Functions: Covalently binds beta-alanine in an ATP-dependent manner to form a thioester bond with its phosphopantetheine group and transfers it to an, as yet, unknown acceptor. May be required for a post-translational protein modification or for post-transcriptional modification of an RNA

The "AASDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AASDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets